vialroom

#cagrilintide 2024-11-20

Wednesday30 messages8 participantstimes are UTC
Highlights from this day
  • vienna_vial — amylin analogue, so its not a GLP-1 at all right 02:29
  • gall_bladder_gav — monotherapy was underwhelming for me and i say that as someone who wanted it to work 05:12
  • gall_bladder_gav — the nausea felt different rather than less, more fullness and less of the queasy wave 05:13
  • void_volume — is anyone running this on its own or is it all CagriSema in here 06:11
VV

its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake

AP

if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way, anyway

titrating dead slow

VV

amylin analogue, so its not a GLP-1 at all right

📉16🎉6⚠️15
AP

noticed something around week 15 on monotherapy, well after i had given up expecting to

CO

dosing them on different days made no difference i could detect, someone check my working

😂3
AP

stopped for 5 months and the fullness went within a fortnight of the last dose

AN

i keep the two on separate days so if something goes wrong i have a chance of knowing which
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist

[edited]

amylin not glp-1

anyone dosing this on a different day to their retatrutide

lost 92lb over 5 months on the combination and i genuinely cannot apportion it, ymmv

CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it

GB

monotherapy was underwhelming for me and i say that as someone who wanted it to work

💀9

the nausea felt different rather than less, more fullness and less of the queasy wave

⚠️17

how do people separate which of the two is doing what in a combination

the slower titration in here is community habit as much as anything, the trials had their own schedule

VB

Digest for the week of 2024-08-12 has been published.

VV

is anyone running this on its own or is it all CagriSema in here

Cited study
Efficacy and Safety of Cagrilintide in Adults with Overweight or Obesity — Phase 2
The Lancet · 2021
Cagrilintide monotherapy, dose ranging. The combination trials came later.
VV

went slower because the first step gave me two rough days and i took that as information

😂5